Pathological cardiac remodeling constitutes a common pathway to heart failure in disease. Despite current pharmacologic therapy and other advances that attenuate remodeling, mortality due to heart failure remains high. New, more effective therapeutic options are desperately needed in an increasing patient population to improve both the survival and quality of life for patients with or susceptible to heart failure. Muscle A-kinase anchoring protein β (mAKAPβ) is the organizer of multimolecular signaling complexes critical for the induction and progression of pathological cardiac remodeling. By binding a diverse set of signaling molecules, mAKAPβ dynamically orchestrates multiple signaling modules that transduce cAMP, mitogen-activated protein kinase (MAPK), Ca2+, phosphoinositide, and hypoxic stress signals. Accordingly, cardiomyocyte-specific mAKAPβ knock-out in mice inhibited remodeling and the development heart failure in multiple models of cardiovascular disease. CRI is a company developing novel, patent protected therapeutics for the prevention and/or treatment of heart failure. In this Fast-Tract SBIR, CRI will test a new gene therapy vector designed to inhibit mAKAPβ expression selectively in the cardiac myocyte by RNA interference. The AAV9sc.shmAKAP biologic is a self- complementary, cardiotropic, serotype 9 adeno-associated virus (AAV9) that expresses an mAKAP-specific small hairpin RNA (shRNA) under the control of a cardiac myocyte-specific promoter. In this application, CRI will test the new biologic in a clinically relevant large animal model for post-myocardial infarction (MI) heart failure. Phase I - Specific Aim: We will perform a dose response curve for the biologic in Yorkshire swine to determine the minimum dose required for consistent inhibition of mAKAPβ expression in the heart. Phase II - Specific Aim 1: Efficacy of mAKAP RNAi for heart failure in a large animal model. The core of this project is to test whether mAKAPβ RNAi will mitigate pathological remodeling induced by MI in swine, preventing heart failure. Swine will be subjected to ischemia-reperfusion to induce MI or sham procedure and then treated with the AAV9sc.shmAKAP biologic by intracoronary infusion immediately after or 1 month later at the dose determined in Phase I. The pigs will be followed by serial echocardiography and studied at endpoint 3 months post-MI by catheterization for left ventricular pressure-volume loop hemodynamics. The goal for this Aim is the demonstration that mAKAP RNAi will preserve cardiac structure and function in a large animal model of MI disease. Specific Aim 2: AAV9sc.shmAKAP-mediated inhibition of the molecular and cellular pathology associated with heart failure. Taking advantage of tissue collected from the same animals used in Aim 1, the benefits of mAKAP RNAi in swine will be demonstrated by gravimetric, histological, and molecular analyses for fibrosis and other markers of cardiac remodeling and heart failure. In addition, initi...